Silverback Therapeutics/$SPRY

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Silverback Therapeutics

ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.

Ticker

$SPRY
Sector
Primary listing

Employees

165

SPRY Metrics

BasicAdvanced
$1B
-
-$0.49
0.92
-

What the Analysts think about SPRY

Analyst ratings (Buy, Hold, Sell) for Silverback Therapeutics stock.

Bulls say / Bears say

The US FDA expanded neffy's label to include patients weighing 15–30 kg, opening access to about 2 million more school-aged children and is expected to accelerate prescriptions during peak seasons (Reuters turn5news13)
As of December 31, 2024, ARS had $314 million in cash, cash equivalents, and short-term investments, supporting operations for at least three years (Refinitiv turn3search2)
In the first quarter of 2025, net product revenue was $7.8 million, with over 5,000 doctors prescribing neffy, highlighting strong early demand in the market (Nasdaq turn7search0)
High SG&A and R&D expenses compared to neffy revenue are limiting profitability: in Q1 2025, SG&A reached $41.1 million while neffy net product revenue was $7.8 million (Nasdaq turn7search0)
An antitrust lawsuit against AptarGroup claims monopolistic control over key nasal spray components, which could disrupt production and increase costs (Reuters turn5news12)
Technical indicators point to overbought conditions, and analyst price targets vary from $28 to $40, indicating potential downside volatility from current price levels (Investing.com turn0search2)
Data summarised monthly by Lightyear AI. Last updated on 4 Oct 2025.

SPRY Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

SPRY Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $SPRY

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs